Despite reducing amyloid plaques, antibody treatments for Alzheimer's fail to improve cognition, highlighting critical gaps ...
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: ...
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
Introduction Despite its serious impact, anorexia nervosa (AN) remains one of the least understood mental illnesses, with significant gaps in effective treatment options. No medications have been ...
Low-intensity shockwave therapy improves erectile function in trials, but guidelines continue to classify it as ...
A large randomized trial in Germany and Spain found that lowering milk protein intake during the second year of life did not ...
SUPPORT II (SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)) is a prospective, randomized controlled study designed to assess the safety and efficacy of the c ...
Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...
In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
These findings are published in the NEJM Evidence in March 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results